You really could not make this up. I have always viewed corporate awards as a complete joke, an excuse for mutual back slapping by folks pouring themselves into DJs and party frocks with shareholders (never invited) picking up the tab for the canapes and champagne. They are always a pointless vanity but this takes the biscuit.
You may remember that in the middle of last year there was a concerted move to pump shares in Eden Research up to a peak of 12p. A highlight of this was Jo Hart’s Midas column which got the IPO date wrong by almost a decade, failed to mention the years of fraud, the condemnation by the FRC, 27 years of non-delivery and instead came up with some made up numbers suggesting that the shares would go from just under 4p to 19p. Shortly thereafter £9.9 million was raised at massively discounted 6.5p. Today we have calendar 2023 numbers.
Thanks to ludicrous pumping by the preposterous Jo Hart of the Mail on Sunday Midas column, who appeared happy to ignore 27 years of non-delivery with a very good sprinkling of fraud, shares in Eden Research (EDEN) surged last year allowing it to get a £9 million placing away at 6.5p. But how quickly is it spaffing that cash? How much is left?
At Companies House, Eden Research’s (EDEN) 29.9% associate TerpeneTech has finally published its long delayed accounts for the year ended 31 December 2022 originally due on 30 September 2023. We can now compare the disclosures made with those made by Eden in its accounts for the year ended 31 December 2022 published on 4 May 2023 in respect of TerpeneTech in Note 15. The results are set out below:
I flagged up that shocking journalism of eight days ago by Jo Hart of the Midas column HERE. But so far her call looks inspired and I look like a schmuck who has received numerous lawyers letter from Eden Research (EDEN) for exposing its numerous historic frauds. Oddly it never went beyond the “bully and harass” stage.
In the c25 years since Eden Research (EDEN) has – as well as committing numerous frauds – managed to send £43.3 million of other folks cash to money heaven. Apologists say that this is an early stage growth company and it is all about the jam that will arrive tomorrow. They have always said that. After a quarter of a century Eden is clearly not early stage and it is not really growing much either. Today come results for calendar 2022.
I have not been to London for almost four years and rather cherish my status as a badly shaven recluse in the boonies so will not be heading to Islington this Saturday as my old pal Jim Mellon holds his annual Master Investor show. As it happens, I am travelling and will have two noisy kids with me and so attendance is impossible. But the ever-entertaining Jim will be speaking as will Evil Knievil so if you are in the hell hole that is London there are far worse things to do this weekend. You can still grab a free ticket HERE. And if you do go, can you do me an enormous favour?
Eden’s (EDEN) 29.9% owned associate TerpeneTech Limited has finally filed its statutory accounts for the year ended 31 December 2021 on 19 December 2022, almost three months past the due date of 30 September 2022.
After 27 years of making losses, lying to investors and engaging in the odd fraud, the laughs continue at Eden Research’s (EDEN). Its 29.9% owned associate TerpeneTech Limited - with which it did a stunning Panama Pump fraud on more than one occasion - still hasn’t managed to file its statutory accounts for the year ended 31 December 2021 which were due on 30 September 2022. As an associate of Eden, Eden is presumed to exercise some degree of influence over TerpeneTech.







